Pharmaceutical News developments in the pharma world, esp. vis a vis the law, etc. 2012-05-08T21:01:29-05:00 admin http://www.howardnations.com/blog/pharma-news/index.php lawscript@gmail.com tag:pivotpowered,2012:PharmaceuticalNews Pivot Copyright (c) 2012, Authors of Pharmaceutical News Fosamax Cases Set for Trial 2011-11-16T19:07:00-05:00 2011-11-16T19:07:00-05:00 tag:pivotpowered,2012:PharmaceuticalNews.59 November 14, 2011. Judge John F. Keenan recently re-scheduled the trial for two bellwether cases in the Fosamax MDL. The trials are now scheduled for September 2012 in the Southern District of New York. A bellwether trial is commonly used in mass torts cases where you have a large number of plaintiffs with similar causes of action. The results of the bellwether trials are then extrapolated to the claims of the other plaintiffs and are used to place value on the cases. This is not a class action. Each individual plaintiff has the right to continue with their own litigation. There are currently 951 active Fosamax cases on file in the Fosamax MDL. November 14, 2011. Judge John F. Keenan recently re-scheduled the trial for two bellwether cases in the Fosamax MDL. The trials are now scheduled for September 2012 in the Southern District of New York. A bellwether trial is commonly used in mass torts cases where you have a large number of plaintiffs with similar causes of action. The results of the bellwether trials are then extrapolated to the claims of the other plaintiffs and are used to place value on the cases. This is not a class action. Each individual plaintiff has the right to continue with their own litigation. There are currently 951 active Fosamax cases on file in the Fosamax MDL. ]]> lcrawford FDA Alerts: Medtronic Model 8637 SynchroMed II Implantable Infusion Pump 2011-11-14T16:22:00-05:00 2011-09-12T14:20:00-05:00 tag:pivotpowered,2012:PharmaceuticalNews.52 September 12, 2011: The FDA reports that, for the Medtronic Model 8637 SynchroMed II Implantable Infusion Pump, there is a Class I Recall due to the potential for reduced battery performance that can lead to the sudden loss of therapy and the return of underlying symptoms and/or therapy withdrawal symptoms. September 12, 2011: The FDA reports that, for the Medtronic Model 8637 SynchroMed II Implantable Infusion Pump, there is a Class I Recall due to the potential for reduced battery performance that can lead to the sudden loss of therapy and the return of underlying symptoms and/or therapy withdrawal symptoms. ]]> lcrawford FDA Alerts: Risperdal and Risperidone 2011-06-21T12:00:00-05:00 2011-06-21T12:00:00-05:00 tag:pivotpowered,2012:PharmaceuticalNews.46 Risperidone (Risperdal) and Ropinirole (Requip): Medication Errors - Name Confusion Healthcare Professionals reminded to clearly print or spell out the medication name on prescriptions. Risperdal (risperidone) and Risperidone: Recall - Uncharacteristic Odor Two lots recalled. Contamination thought to be the result of a chemical preservative applied to wood used in the construction of pallets on which materials are transported and stored. Risperidone (Risperdal) and Ropinirole (Requip): Medication Errors - Name Confusion
 Healthcare Professionals reminded to clearly print or spell out the medication name on prescriptions.

Risperdal (risperidone) and Risperidone: Recall - Uncharacteristic Odor
 Two lots recalled. Contamination thought to be the result of a chemical preservative applied to wood used in the construction of pallets on which materials are transported and stored.

]]> lcrawford Yaz / Yasmin Status Conference 2010-03-26T14:06:00-05:00 2010-03-26T14:06:00-05:00 tag:pivotpowered,2012:PharmaceuticalNews.37 A status conference has been scheduled for April 14, 2010 at 9:00 a.m. before Judge David R. Herndon in the U.S. District Court, Southern District of Illinois. The conference is regarding the “Yasmin and Yaz (Drospirenone) Marketing, Sales Practice and Products Liability Litigation.” This multi-district litigation (MDL) consists of cases nationwide alleging serious injuries and deaths stemming from the use of Yaz or Yasmin birth control pills. A status conference is a pre-trial meeting where the attorneys inform the judge as to how the case is proceeding, what discovery has been completed, settlement negotiations that have occurred, and any other matters relevant to moving the case toward trial. Posted March 26, 2010By Cindy L. Nations A status conference has been scheduled for April 14, 2010 at 9:00 a.m. before Judge David R. Herndon in the U.S. District Court, Southern District of Illinois. The conference is regarding the “Yasmin and Yaz (Drospirenone) Marketing, Sales Practice and Products Liability Litigation.” This multi-district litigation (MDL) consists of cases nationwide alleging serious injuries and deaths stemming from the use of Yaz or Yasmin birth control pills. A status conference is a pre-trial meeting where the attorneys inform the judge as to how the case is proceeding, what discovery has been completed, settlement negotiations that have occurred, and any other matters relevant to moving the case toward trial.

Posted March 26, 2010
By Cindy L. Nations
]]> lcrawford Trasylol Pretrial Conference 2010-03-26T13:15:00-05:00 2010-03-26T13:15:00-05:00 tag:pivotpowered,2012:PharmaceuticalNews.36 A Pretrial Conference is scheduled for Thursday, April 1, 2010 at 1:30 p.m. before Judge Donald M. Middlebrooks in the U.S. District Court, Southern District of Florida, West Palm Beach Division. This is in the Trasylol multi-district litigation consisting of nation-wide lawsuits alleging kidney failure, heart attack, MI, stroke, and death resulting from the surgical drug Trasylol. The purpose of the conference is to discuss FDA issues.Posted March 26, 2010By Cindy L. Nations A Pretrial Conference is scheduled for Thursday, April 1, 2010 at 1:30 p.m. before Judge Donald M. Middlebrooks in the U.S. District Court, Southern District of Florida, West Palm Beach Division. This is in the Trasylol multi-district litigation consisting of nation-wide lawsuits alleging kidney failure, heart attack, MI, stroke, and death resulting from the surgical drug Trasylol. The purpose of the conference is to discuss FDA issues.

Posted March 26, 2010
By Cindy L. Nations
]]> lcrawford